-

01:16:49 PM

MDNA Stock News

MDNA - Medicenna Therapeutics Corp

05/11/22 7:00 AM

Nasdaq : MDNA

clinical trial

Medicenna Presents Phase 1/2 ABILITY Study Data Highlighting MDNA11’s Favorable Clinical Profile at the 2022 Frontiers in Cancer Immunotherapy Meeting

MDNA11 selectively increased a sub-population of anti-tumor ICOS + CD8 T cells without enhancing proliferation of highly immune-suppressive

RHEA-AI

neutral

05/02/22 8:00 AM

Nasdaq : MDNA

clinical trial

Medicenna Announces New Clinical Data Showing Dose-Dependent Stimulation of Anti-Cancer Immune Cells with MDNA11 in the Phase 1/2 ABILITY Study

NK cell / Treg and CD8 + T cell / Treg ratios increased by 4.4-fold and 2.6 fold, respectively, at the 30 µg/kg dose,

RHEA-AI

neutral

04/27/22 7:00 AM

Nasdaq : MDNA

conferences

Medicenna Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference

Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President and CEO and Elizabeth Williams, CFO of Medicenna, will attend

RHEA-AI

neutral

04/08/22 9:14 AM

Nasdaq : MDNA

clinical trial

Medicenna Announces Preclinical Data Highlighting the Potent Anti-Tumor Efficacy of Anti-PD1-IL-2 BiSKIT at the AACR Annual Meeting

Treatment with anti-PD-1-IL-2 BiSKIT led to statistically significant improvements in tumor growth

RHEA-AI

positive

04/08/22 9:10 AM

Nasdaq : MDNA

clinical trial

Medicenna Presents Preclinical Data Demonstrating Anti-Cancer Activity of a Long-Acting IL-13 Super-Antagonist at the AACR Annual Meeting

RHEA-AI

neutral

03/10/22 7:00 AM

Nasdaq : MDNA

conferences

Medicenna Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference

Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medicenna, will present a

RHEA-AI

neutral

03/09/22 7:00 AM

Nasdaq : MDNA

Medicenna Announces Upcoming Poster Presentations at the AACR Annual Meeting

Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced the publication of two abstracts that have been accepted for electronic poster presentations at

RHEA-AI

neutral

03/03/22 7:00 AM

Nasdaq : MDNA

management

Medicenna Announces Appointment of Clinical Advisory Board and Dr. Kapil Dhingra as Strategic Advisor

Medicenna’s Clinical Advisory Board is comprised of thought leaders in immuno-oncology with experience in clinical development of Proleukin® and next generation IL-2 Dr. Dhingra has a track record of development and approval of cancer therapies and extensive board level expertise resulting in

RHEA-AI

very positive

02/10/22 7:00 AM

Nasdaq : MDNA

conferences

Medicenna to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medicenna, will participate

RHEA-AI

neutral

02/09/22 7:00 AM

Nasdaq : MDNA

earnings

Medicenna Reports Third Quarter Fiscal 2022 Financial Results and Operational Highlights

RHEA-AI

positive

1 2 3 4 5 6 7 Next

MDNA Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.medicenna.com
Security nameMedicenna Therapeutics Corp
Issue typecs
SectorManufacturing
Sic code2834
Employees2021
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing

About Medicenna Therapeutics Corp

Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines for the treatment of a broad range of cancers. Medicenna's long-acting IL2 Superkine asset, MDNA11, is a next-generation IL-2 with superior CD122 binding without CD25 affinity and therefore preferentially stimulates cancer killing effector T cells and NK cells when compared to competing IL-2 programs. Medicenna's lead IL4 Empowered Superkine, MDNA55, has completed a Phase 2b clinical trial for rGBM, the most common and uniformly fatal form of brain cancer. MDNA55 has been studied in five clinical trials involving 132 subjects, including 112 adults with rGBM. MDNA55 has obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA, respectively.